Clinical Trial Update: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for IMM2902 in patients with HER2-expressing advanced solid tumors including advanced solid tumors, advanced lung cancer, advanced gastri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gastric Carcinoma
• Lung Cancer
• Solid Tumor

Drugs mentioned

• IMM2902

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: Advanced Solid Tumor, Advanced Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN